These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21366850)

  • 1. Cardiovascular events in subgroups of patients during primary treatment of hypertension with candesartan or losartan.
    Russell D; Stålhammar J; Bodegard J; Hasvold P; Thuresson M; Kjeldsen SE
    J Clin Hypertens (Greenwich); 2011 Mar; 13(3):189-97. PubMed ID: 21366850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension.
    Kjeldsen SE; Stålhammar J; Hasvold P; Bodegard J; Olsson U; Russell D
    J Hum Hypertens; 2010 Apr; 24(4):263-73. PubMed ID: 19890371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring.
    Baguet JP; Nisse-Durgeat S; Mouret S; Asmar R; Mallion JM
    Int J Clin Pract; 2006 Apr; 60(4):391-8. PubMed ID: 16620350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension.
    Zhenfeng Zheng ; Huilan Shi ; Junya Jia ; Dong Li ; Shan Lin
    J Renin Angiotensin Aldosterone Syst; 2011 Sep; 12(3):365-74. PubMed ID: 21421652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan.
    Andersson OK; Neldam S
    Blood Press; 1998 Jan; 7(1):53-9. PubMed ID: 9551878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Candesartan cilexetil vs losartan.
    Bunt T
    Blood Press; 1998 Jul; 7(4):251-2. PubMed ID: 9858118
    [No Abstract]   [Full Text] [Related]  

  • 7. [Angiotensin-II receptor inhibitors in hemodialysed uremia patients with arterial hypertension: candesartan cilexitil versus losartan].
    Cice G; Ferrara L; Tagliamonte E; Russo PE; Di Benedetto A; Iacono A
    Cardiologia; 1999 Dec; 44(12):1071-6. PubMed ID: 10687258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex).
    Ogihara T; Ueshima K; Nakao K; Fukiyama K; Oba K; Yasuno S; Fujimoto A; Sato T; Matsuoka H; Saruta T;
    Hypertens Res; 2011 Dec; 34(12):1295-301. PubMed ID: 21833000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators.
    Manolis AJ; Grossman E; Jelakovic B; Jacovides A; Bernhardi DC; Cabrera WJ; Watanabe LA; Barragan J; Matadamas N; Mendiola A; Woo KS; Zhu JR; Mejia AD; Bunt T; Dumortier T; Smith RD
    Clin Ther; 2000 Oct; 22(10):1186-203. PubMed ID: 11110230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial.
    Lithell H; Hansson L; Skoog I; Elmfeldt D; Hofman A; Olofsson B; Trenkwalder P; Zanchetti A;
    J Hypertens; 2003 May; 21(5):875-86. PubMed ID: 12714861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial.
    Ogihara T; Nakao K; Fukui T; Fukiyama K; Ueshima K; Oba K; Sato T; Saruta T;
    Hypertension; 2008 Feb; 51(2):393-8. PubMed ID: 18172059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15,990 patients.
    Hasvold LP; Bodegård J; Thuresson M; Stålhammar J; Hammar N; Sundström J; Russell D; Kjeldsen SE
    J Hum Hypertens; 2014 Nov; 28(11):663-9. PubMed ID: 25211055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effects of candesartan cilexetil and losartan in patients with systemic hypertension. Candesartan Versus Losartan Efficacy Comparison (CANDLE) Study Group.
    Gradman AH; Lewin A; Bowling BT; Tonkon M; Deedwania PC; Kezer AE; Hardison JD; Cushing DJ; Michelson EL
    Heart Dis; 1999; 1(2):52-7. PubMed ID: 11720604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada: A Population-Based Time Series Analysis.
    Leclerc J; Blais C; Rochette L; Hamel D; Guénette L; Poirier P
    Circ Cardiovasc Qual Outcomes; 2017 Oct; 10(10):. PubMed ID: 28974512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Candesartan cilexetil--a review of effects on cardiovascular complications in hypertension and chronic heart failure.
    Meredith PA
    Curr Med Res Opin; 2007 Jul; 23(7):1693-705. PubMed ID: 17588300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Losartan study investigators.
    Lacourcière Y; Asmar R
    Am J Hypertens; 1999 Dec; 12(12 Pt 1-2):1181-7. PubMed ID: 10619580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis.
    Grosso AM; Bodalia PN; Macallister RJ; Hingorani AD; Moon JC; Scott MA
    Int J Clin Pract; 2011 Mar; 65(3):253-63. PubMed ID: 21284790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Examining the association of olmesartan and other angiotensin receptor blockers with overall and cause-specific mortality.
    Lin JW; Chang CH; Caffrey JL; Wu LC; Lai MS
    Hypertension; 2014 May; 63(5):968-76. PubMed ID: 24516110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of a combination tablet of candesartan cilexetil and hydrochlorothiazide in insufficiently controlled primary hypertension--comparison with a combination of losartan and hydrochlorothiazide.
    Ohma KP; Milon H; Valnes K
    Blood Press; 2000; 9(4):214-20. PubMed ID: 11055474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial.
    Suzuki H; Kanno Y; Sugahara S; Ikeda N; Shoda J; Takenaka T; Inoue T; Araki R
    Am J Kidney Dis; 2008 Sep; 52(3):501-6. PubMed ID: 18653268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.